- The shares of the clinical-stage biotechnology company Recursion Pharmaceuticals (RXRX -10.2%) are set to close at an all-time low on Thursday after the company announced a delay for its Phase 2 trial for REC-3599 in rare genetic disorder, infantile GM2 gangliosidosis (GM).
- Recursion's leadership has decided that a dose optimization study in sheep of Tay-Sachs disease will be in the best interests of patients before the enrollment of the trial can begin.
- The decision will delay the start of the mid-stage trial by approximately two years, the company said. Previously, Recursion (NASDAQ:RXRX) said it would begin the trial in the first half of 2022.
- Meanwhile, citing challenges posed by the Omicron variant in opening clinical sites, the company said that the enrollment of the first patient in its Phase 2 study for REC-4881 in Familial Adenomatous Polyposis is likely in either Q2 or Q3 2022. In November, the management said that the trial would begin in H1 2022.
Recommended For You
More Trending News
See More »